March 13th Options Now Available For Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) is trading at $227.33 and the article analyzes two options strategies: selling the $220 put (bid $1.50) would commit an investor to buy at $220 with a net basis of $218.50 and, given a ~3% OTM strike, has a 69% chance to expire worthless, implying a 0.68% return (5.79% annualized). Selling a covered $230 call (bid $3.20) against shares bought at $227.33 would cap upside at $230 but generate a 2.58% return to the March 13 expiration with a 54% chance to expire worthless (1.41% boost, 11.96% annualized); implied volatilities are ~21% (put) and ~20% (call) versus a trailing 12‑month volatility of 19%.

Analysis

Market structure: Short-dated option sellers and income-focused accounts benefit most — selling the JNJ Mar13 $220 put nets $1.50 (cost basis $218.50) and has a ~69% chance to expire worthless; covered-call sellers at $230 net $3.20 with ~54% chance to keep premium. JNJ’s steady realized vol (19%) vs IV (20–21%) signals mild risk premium; this favors premium harvesting but not aggressive directional bets. Large-scale put assignments could transiently bid the stock, but fundamentals-driven flows dominate long-term share price.

Risk assessment: Tail risks include negative FDA rulings, multi-billion litigation shocks, or broad market volatility that could spike IV >40% and blow up short-put positions; these are low-probability but high-impact over 1–6 months. Near-term (days–weeks) risk is assignment and ex-dividend early exercise; medium-term (months) risk is earnings/FDA catalysts; long-term (quarters+) is litigation/product cycle. Hidden dependencies: margin/rehypothecation, correlation with bond rates (defensive rotation) and hedge fund gamma exposures can amplify moves.

Trade implications: Direct actionable plays — sell cash-secured Mar13 $220 puts if willing to own at $218.50 (size 1–2% portfolio), or a defined-risk $220/$210 put credit spread (width $10) sized 0.5–1%. If already long JNJ, sell Mar13 $230 covered calls to boost carry (target 2.6% to assignment; roll if stock >$235 or IV falls >5 pts). For tail protection buy 3–6 month 5–10% OTM puts (allocate 0.5%–1%).

Contrarian angles: Consensus underestimates capital efficiency costs — premiums annualize high (5.8%–12% shown) but require capital lock and assignment risk; market is underpricing event tails (IV only ~2 pts above realized). Historical parallel: blue‑chip put-selling in low-vol regimes performs until a regime shock; so prefer defined-risk structures or small allocations. Mispricing opportunity: modestly richer compensation for selling downside protection versus buying long-term protection at current IVs below 25%.

Key Decisions for Investors

• Sell-to-open JNJ Mar13 $220 cash-secured puts collecting $1.50 (effective buy at $218.50) sized to 1–2% of portfolio; close/buy back if JNJ < $212 or if premium decays by 50% (take-profit), and cap allocation to avoid >10% cash tie-up.
• If you want defined risk, sell a JNJ Mar13 $220/$210 put credit spread (width $10) sized to 0.5–1% portfolio; accept max loss = $10 minus credit, and exit if spread mark-to-market reaches 30% of max loss or if IV rises >5 vol points.
• If already long JNJ shares, sell Mar13 $230 covered calls (collect $3.20) to lock a 2.58% near-term return; plan to roll up-and-out if JNJ > $235 or buy back if IV compresses >5 pts or premium falls 60%.
• Buy 3–6 month JNJ protective puts (5–10% OTM) allocating 0.5–1% portfolio as tail insurance against FDA/litigation shocks; reduce or sell protection if IV >30% or after decisive catalyst outcome within 30–90 days.